Synergistic antitumor activity of troxacitabine and camptothecin in selected human cancer cell lines

Molecular Pharmacology

Volumn 66, Issue 2, 2004, Pages 285-292

  Kim, Tracy E ^a   Park, Shin Young ^b   Hsu, Chih Hung ^b   Dutschman, Ginger E ^b   Cheng, Yung Chi ^b  

^a YALE CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CISPLATIN; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DNA; DOUBLE STRANDED DNA; ETOPOSIDE; IRINOTECAN; METHYLENE BLUE; PROTEIN; TROXACITABINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG METABOLISM; DRUG POTENTIATION; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL SURVIVAL; CYTOSINE; DEOXYCYTIDINE KINASE; DIOXOLANES; DNA DAMAGE; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; KB CELLS; TUMOR CELLS, CULTURED;

EID: 3343020677     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.66.2.285     Document Type: Article

References (40)

1. Bahadori HR, Green MR, and Catapano CV (2001) Synergistic interaction between topotecan and microtubule-interfering agents. Cancer Chemother Pharmacol 48:188-196.
2. Beidler DR, Chang JY, Zhou BS, and Cheng YC (1996) Camptothecin resistance involving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines. Cancer Res 56:345-353.
3. Beidler DR and Cheng YC (1995) Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Mol Pharmacol 47:907-914.
4. Bowlin T, Genne P, Kadhim S, Gourdeau H, and Attardo G (1997) A novel cytidine nucleoside analogue, BCH 4556, with potent activity against human anthracycline-resistant leukemia (Abstract). Proc Am Assoc Cancer Res 38:100.
5. Burris HA 3rd, Awada A, Kuhn JG, Eckardt JR, Cobb PW, Rinaldi DA, Fields S, Smith L, and Von Hoff DD (1994) Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion. Anticancer Drugs 5:394-402.
6. Chang CN, Doong SL, Zhou JH, Beach JW, Jeong LS, Chu CK, Tsai CH, Cheng YC, Liotta D, and Schinazi R (1992) Deoxycytidine deaminase-resistant stereoisomer is the active form of (±)-2′,3′-dideoxy- 3′-thiacytidine in the inhibition of hepatitis B virus replication. J Biol Chem 267:13938-13942.
7. Cheng YC, Dommin B, and Lee LS (1977) Human deoxycytidine kinase. Purification and characterization of the cytoplasmic and mitochondrial isozymes derived from blast cells of acute myelocytic leukemia patients. Biochim Biophys Acta 481:481-492.
8. Cheng YC, Dutschman G, De Clereq E, Jones AS, Rahim SG, Verhelst G, and Walker RT (1981) Differential affinities of 5-(2-halogenovinyl)-2′- deoxyuridines for deoxythymidine kinases of various origins. Mol Pharmacol 20:230-233.
9. Chou KM, Kukhanova M, and Cheng YC (2000) A novel action of human apurinic/apyrimidinic endonuclease: excision of L-configuration deoxyribonucleoside analogs from the 3′ termini of DNA. J Biol Chem 275:31009-31015.
10. Coates JA, Cammack N, Jenkinson HJ, Mutton IM, Pearson BA, Storer R, Cameron JM, and Penn CR (1992) The separated enantiomers of 2′-deoxy- 3′-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob Agents Chemother 36:202-205.
11. Csapo Z, Keszler G, Safrany G, Spasokoukotskaja T, Talianidis I, Staub M, and Sasvari-Szekely M (2003) Activation of deoxycytidine kinase by gamma-irradiation and inactivation by hyperosmotic shock in human lymphocytes. Biochem Pharmacol 65:2031-2039.
12. Csapo Z, Sasvari-Szekely M, Spasokoukotskaja T, Talianidis I, Eriksson S, and Staub M (2001) Activation of deoxycytidine kinase by inhibition of DNA synthesis in human lymphocytes. Biochem Pharmacol 61:191-197.
13. de Bono JS, Stephenson J Jr, Baker SD, Hidalgo M, Patnaik A, Hammond LA, Weiss G, Goetz A, Sin L, Simmons C, et al. (2002) Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. J Clin Oncol 20:96-109.
14. Distefano M, Ferlini C, De Vincenzo R, Gaggini C, Mancuso S, and Scambia G (2000) Antagonistic effect of the combination gemcitabine/topotecan in ovarian cancer cells. Oncol Res 12:355-359.
15. Giles FJ, Cortes JE, Baker SD, Thomas DA, O'Brien S, Smith TL, Beran M, Bivins C, Jolivet J, and Kantarjian HM (2001) Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. J Clin Oncol 19:762-771.
16. Giles FJ, Faderl S, Thomas DA, Cortes JE, Garcia-Manero G, Douer D, Levine AM, Koller CA, Jeha SS, O'Brien SM, et al. (2003) Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. J Clin Oncol 21:1050-1056.
17. Giles FJ, Garcia-Manero G, Cortes JE, Baker SD, Miller CB, O'Brien SM, Thomas DA, Andreeff M, Bivins C, Jolivet J, et al. (2002) Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. J Clin Oncol 20:656-664.
18. Gourdeau H, Bibeau L, Ouellet F, Custeau D, Bernier L, and Bowlin T (2001a) Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity. Cancer Chemother Pharmacol 47:236-240.
19. Gourdeau H, Clarke ML, Ouellet F, Mowles D, Selner M, Richard A, Lee N, Mackey JR, Young JD, Jolivet J, et al. (2001b) Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines. Cancer Res 61:7217-7224.
20. Gourdeau H, Genne P, Kadhim S, Bibeau L, Duchamp O, Ouellet F, DeMuys JM, Bouffard DY, and Attardo G (2002) Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts. Cancer Chemother Pharmacol 50:490-496.
21. Grove KL and Cheng YC (1996) Uptake and metabolism of the new anticancer compound beta-L-(-)-dioxolane-cytidine in human prostate carcinoma DU-145 cells. Cancer Res 56:4187-4191.
22. Grove KL, Guo X, Liu SH, Gao Z, Chu CK, and Cheng YC (1995) Anticancer activity of beta-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration. Cancer Res 55:3008-3011.
23. Hatzis P, Al-Madhoon AS, Jullig M, Petrakis TG, Eriksson S, and Talianidis I (1998) The intracellular localization of deoxycytidine kinase. J Biol Chem 273:30239-30243.
24. Kadhim SA, Bowlin TL, Waud WR, Angers EG, Bibeau L, DeMuys JM, Bednarski K, Cimpoia A, and Attardo G (1997) Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models. Cancer Res 57:4803-4810.
25. Kim HO, Shanmiganathan K, Alves AJ, Jeong LS, Beach JW, Schinazi RF, Chang CN, Cheng YC, and Chu CK (1992) Potent anti-HIV and anti-HBV activities of (-)-L-B-dioxolane-C and (+)-D-B-dioxolane-T and their asymmetric syntheses. Tetrahedron Lett 33:6899-6902.
26. Krishnan P, Liou JY, and Cheng YC (2002) Phosphorylation of pyrimidine L-deoxynucleoside analog diphosphates. Kinetics of phosphorylation and dephosphorylation of nucleoside analog diphosphates and triphosphates by 3-phosphoglycerate kinase. J Biol Chem 277:31593-31600.
27. Kukhanova M, Liu SH, Mozzherin D, Lin TS, Chu CK, and Cheng YC (1995) L- and D-enantiomers of 2′,3′-dideoxycytidine 5′-triphosphate analogs as substrates for human DNA polymerases. Implications for the mechanism of toxicity. J Biol Chem 270:23055-23059.
28. Liou JY, Dutschman GE, Lam W, Jiang Z, and Cheng YC (2002) Characterization of human UMP/CMP kinase and its phosphorylation of D- and L-form deoxycytidine analogue monophosphates. Cancer Res 62:1624-1631.
29. Loewe S (1953) The problem of synergism and antagonism of combined drugs. Arzneim-Forsch 3:285-320.
30. Negoro S, Fukuoka M, Masuda N, Takada M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Niitani H, and Taguchi T (1991) Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 83:1164-1168.
31. Ooi K, Ohkubo T, Higashigawa M, Kawasaki H, and Sakurai M (1996) Increased deoxycytidine kinase activity by etoposide in L1210 murine leukemic cells. Biol Pharm Bull 19:1382-1383.
32. Pourquier P, Gioffre C, Kohlhagen G, Urasaki Y, Goldwasser F, Hertel LW, Yu S, Pon RT, Gmeiner WH, and Pommier Y (2002) Gemcitabine (2′,2′- difluoro-2′-deoxycytidine), an antimetabolite that poisons topoisomerase I. Clin Cancer Res 8:2499-504.
33. Pourquier P, Takebayashi Y, Urasaki Y, Gioffre C, Kohlhagen G, and Pommier Y (2000) Induction of topoisomerase I cleavage complexes by 1-beta -D-arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells. Proc Natl Acad Sci USA 97:1885-1890.
34. Rabbani SA, Harakidas P, Bowlin T, and Attardo G (1998) Effect of nucleoside analogue BCH-4556 on prostate cancer growth and metastases in vitro and in vivo. Cancer Res 58:3461-3465.
35. Schinazi RF, Chu CK, Peck A, McMillan A, Mathis R, Cannon D, Jeong LS, Beach JW, Choi WB, Yeola S, et al. (1992) Activities of the four optical isomers of 2′,3′-dideoxy-3′-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes. Antimicrob Agents Chemother 36:672-676.
36. Tolis C, Peters GJ, Ferreira CG, Pinedo HM, and Giaccone G (1999) Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur J Cancer 35:796-807.
37. Townsley CA, Chi K, Ernst DS, Belanger K, Tannock I, Bjarnason GA, Stewart D, Goel R, Ruether JD, Siu LL, et al. (2003) Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 21:1524-1529.
38. Wall ME, Wani MC, Cooke CE, Palmer KH, McPhail AT, and Slim GA (1966) The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88:3888-3890.
39. Weitman S, Marty J, Jolivet J, Locas C, and Von Hoff DD (2000) The new dioxolane, (-)-2′-deoxy-3′-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts. Clin Cancer Res 6:1574-1578.
40. Wu J, Yin MB, Hapke G, Toth K, and Rustum YM (2002) Induction of biphasic DNA double strand breaks and activation of multiple repair protein complexes by DNA topoisomerase I drug 7-ethyl-10-hydroxy-camptothecin. Mol Pharmacol 61:742-748.